Effect of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation 5-Year Follow-Up of the IVUS-XPL Randomized Trial

被引:166
作者
Hong, Sung-lin [1 ]
Mintz, Gary S. [2 ]
Ahn, Chul-Min [1 ]
Kim, Jung-Sun [1 ]
Kim, Byeong-Keuk [1 ]
Ko, Young-Guk [1 ]
Kang, Tae-Soo [3 ]
Kang, Woong-Chol [4 ]
Kim, Yong Hoon [5 ]
Hur, Seung-Ho [6 ]
Hong, Bum-Kee [7 ]
Choi, Donghoon [1 ]
Kwon, Hyuckmoon [7 ]
Jang, Yangsoo [1 ]
Hong, Myeong-Ki [1 ]
机构
[1] Yonsei Univ Hlth Syst, Severance Cardiovasc Hosp, Seoul, South Korea
[2] Cardiovasc Res Fdn, New York, NY USA
[3] Dankook Univ, Coll Med, Cheonan, South Korea
[4] Gachon Univ, Gil Hosp, Coll Med, Incheon, South Korea
[5] Kangwon Natl Univ, Sch Med, Chunchon, South Korea
[6] Keimyung Univ, Coll Med, Daegu, South Korea
[7] Gangnam Severance Hosp, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
coronary artery disease; drug-eluting stent; intravascular ultrasound; CLINICAL-OUTCOMES; EVEROLIMUS; THROMBOSIS; LESIONS; SAFETY; SORT;
D O I
10.1016/j.jcin.2019.09.033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The goal of this study was to evaluate whether the beneficial effect of use of intravascular ultrasound (IVUS) is sustained for long-term follow-up. BACKGROUND The use of IVUS promoted favorable 1-year clinical outcome in the IVUS-XPL (Impact of Intravascular Ultrasound Guidance on the Outcomes of Xience Prime Stents in Long Lesions) trial. It is not known, however, whether this effect is sustained for long-term follow-up. METHODS The IVUS-XPL trial randomized 1,400 patients with long coronary lesions (implanted stent length >= 28 mm) to receive IVUS-guided (n = 700) or angiography-guided (n = 700) everolimus-eluting stent implantation. Five-year clinical outcomes were investigated in patients who completed the original trial. The primary outcome was the composite of major adverse cardiac events, including cardiac death, target lesion-related myocardial infarction, or ischemia-driven target lesion revascularization at 5 years, analyzed by intention-to-treat. RESULTS Five-year follow-up was completed in 1,183 patients (85%). Major adverse cardiac events at 5 years occurred in 36 patients (5.6%) receiving IVUS guidance and in 70 patients (10.7%) receiving angiographic guidance (hazard ratio: 0.50; 95% confidence interval: 0.34 to 0.75; p = 0.001). The difference was driven mainly by a lower risk for target lesion revascularization (31 [4.8%] vs. 55 [8.4%]; hazard ratio: 0.54; 95% confidence interval: 0.33 to 0.89; p = 0.007). By landmark analysis, major adverse cardiac events between 1 and 5 years occurred in 17 patients (2.8%) receiving IVUS guidance and in 31 patients (5.2%) receiving angiographic guidance (hazard ratio: 0.53; 95% confidence interval: 0.29 to 0.95; p = 0.031). CONCLUSIONS Compared with angiography-guided stent implantation, IVUS-guided stent implantation resulted in a significantly lower rate of major adverse cardiac events up to 5 years. Sustained 5-year clinical benefits resulted from both within 1 year and from 1 to 5 years post-implantation. (Impact of Intravascular Ultrasound Guidance on the Outcomes of Xience Prime Stents in Long Lesions [IVUS-XPL Study]: Retrospective and Prospective Follow-Up Study; NCT03866486) (c) 2020 by the American College of Cardiology Foundation.
引用
收藏
页码:62 / 71
页数:10
相关论文
共 22 条
  • [1] Intravascular Ultrasound Guidance Is Associated With Better Outcome in Patients Undergoing Unprotected Left Main Coronary Artery Stenting Compared With Angiography Guidance Alone
    Andell, Pontus
    Karlsson, Sofia
    Mohammad, Moman A.
    Gotberg, Matthias
    James, Stefan
    Jensen, Jens
    Frobert, Ole
    Angeras, Oskar
    Nilsson, Johan
    Omerovic, Elmir
    Lagerqvist, Bo
    Persson, Jonas
    Koul, Sasha
    Erlinge, David
    [J]. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2017, 10 (05)
  • [2] A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: The AVIO trial
    Chieffo, Alaide
    Latib, Azeem
    Caussin, Christophe
    Presbitero, Patrizia
    Galli, Stefano
    Menozzi, Alberto
    Varbella, Ferdinando
    Mauri, Fina
    Valgimigli, Marco
    Arampatzis, Chourmouzios
    Sabate, Manuel
    Erglis, Andrejs
    Reimers, Bernhard
    Airoldi, Flavio
    Laine, Mika
    Lopez Palop, Ramon
    Mikhail, Ghada
    MacCarthy, Philip
    Romeo, Francesco
    Colombo, Antonio
    [J]. AMERICAN HEART JOURNAL, 2013, 165 (01) : 65 - 72
  • [3] Impact of Intravascular Ultrasound-Guided Percutaneous Coronary Intervention on Long-Term Clinical Outcomes in Patients Undergoing Complex Procedures
    Choi, Ki Hong
    Song, Young Bin
    Lee, Joo Myung
    Lee, Sang Yoon
    Park, Taek Kyu
    Yang, Jeong Hoon
    Choi, Jin-Ho
    Choi, Seung-Hyuk
    Gwon, Hyeon-Cheol
    Hahn, Joo-Yong
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (07) : 607 - 620
  • [4] Clinical end points in coronary stent trials - A case for standardized definitions
    Cutlip, Donald E.
    Windecker, Stephan
    Mehran, Roxana
    Boam, Ashley
    Cohen, David J.
    van Es, Gerrit-Anne
    Steg, P. Gabriel
    Morel, Marie-angele
    Mauri, Laura
    Vranckx, Pascal
    McFadden, Eugene
    Lansky, Alexandra
    Hamon, Martial
    Krucoff, Mitchell W.
    Serruys, Patrick W.
    [J]. CIRCULATION, 2007, 115 (17) : 2344 - 2351
  • [5] Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease
    Dangas, George D.
    Serruys, Patrick W.
    Kereiakes, Dean J.
    Hermiller, James
    Rizvi, Ali
    Newman, William
    Sudhir, Krishnankutty
    Smith, Robert S., Jr.
    Cao, Sherry
    Theodoropoulos, Kleanthis
    Cutlip, Donald E.
    Lansky, Alexandra J.
    Stone, Gregg W.
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2013, 6 (09) : 914 - 922
  • [6] 5-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting Stents Final Results From the SPIRIT III Trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)
    Gada, Hemal
    Kirtane, Ajay J.
    Newman, William
    Sanz, Mark
    Hermiller, James B.
    Mahaffey, Kenneth W.
    Cutlip, Donald E.
    Sudhir, Krishnankutty
    Hou, Liming
    Koo, Kai
    Stone, Gregg W.
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2013, 6 (12) : 1263 - 1266
  • [7] Current Management of In-Stent Restenosis
    Her, Ae-Young
    Shin, Eun-Seok
    [J]. KOREAN CIRCULATION JOURNAL, 2018, 48 (05) : 337 - 349
  • [8] Effect of Intravascular Ultrasound-Guided vs Angiography-Guided Everolimus-Eluting Stent Implantation The IVUS-XPL Randomized Clinical Trial
    Hong, Sung-Jin
    Kim, Byeong-Keuk
    Shin, Dong-Ho
    Nam, Chung-Mo
    Kim, Jung-Sun
    Ko, Young-Guk
    Choi, Donghoon
    Kang, Tae-Soo
    Kang, Woong-Chol
    Her, Ae-Young
    Kim, Yonghoon
    Hur, Seung-Ho
    Hong, Bum-Kee
    Kwon, Hyuckmoon
    Jang, Yangsoo
    Hong, Myeong-Ki
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (20): : 2155 - 2163
  • [9] Long-Term Health Outcome and Mortality Evaluation After Invasive Coronary Treatment Using Drug Eluting Stents with or without the IVUS Guidance. Randomized Control Trial. HOME DES IVUS
    Jakabcin, Jozef
    Spacek, Radim
    Bystron, Marian
    Kvasnak, Martin
    Jager, Jiri
    Veselka, Josef
    Kala, Petr
    Cervinka, Pavel
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2010, 75 (04) : 578 - 583
  • [10] Safety and Efficacy of Everolimus-Versus Sirolimus-Eluting Stents 5-Year Results From SORT OUT IV
    Jensen, Lisette Okkels
    Thayssen, Per
    Christiansen, Evald Hoj
    Maeng, Michael
    Ravkilde, Jan
    Hansen, Knud Norregaard
    Hansen, Henrik Steen
    Krusell, Lars
    Kaltoft, Anne
    Tilsted, Hans Henrik
    Berencsi, Klara
    Junker, Anders
    Lassen, Jens Flensted
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (07) : 751 - 762